RASD2 and Parkinson disease: Overall, considering, on one hand, the potential toxicity of rapamycin and related drugs as inhibitors of protein synthesis and, on the other, the negligible levels of Rhes in peripheral tissues, these findings pave the way toward a potential use of Rhes inhibitors in PD therapy to counteract LID, with no detrimental impact on L-DOPA efficacy (Figure 1).